BioSig Technologies logo

BioSig TechnologiesNASDAQ: BSGM

Profile

Sector:

Healthcare

Country:

United States

IPO:

31 October 2014

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$15.81 M
-88%vs. 3y high
22%vs. sector
-vs. 3y high
-vs. sector
-2.64 K
-724%vs. 3y high
1%vs. sector
395.36
-83%vs. 3y high
97%vs. sector

Price

after hours | 9 min ago
$0.97+$0.10(+11.86%)

Dividend

No data over the past 3 years
$13.00 K-$3.92 M

Analysts recommendations

Institutional Ownership

BSGM Latest News

BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
globenewswire.com22 October 2024 Sentiment: POSITIVE

Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or the “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company's common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities (“MVLS”) requirement previously became non-compliant.

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer
globenewswire.com10 June 2024 Sentiment: POSITIVE

Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.   Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa.

BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
globenewswire.com30 May 2024 Sentiment: POSITIVE

Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unregistered warrants to purchase up to 1,570,683 shares of common stock at an exercise price of $1.78 per share. The unregistered warrants are immediately exercisable and will expire five years from the date of issuance.

BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
Zacks Investment Research25 August 2023 Sentiment: POSITIVE

BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.

Why Is BioSig Technologies (BSGM) Stock Up 19% Today?
InvestorPlace20 July 2023 Sentiment: POSITIVE

BioSig Technologies (NASDAQ: BSGM ) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia's (NASDAQ: NVDA ) Inception program. The Inception program is one that Nvidia uses to select companies with promising developments in the AI and data sciences spaces.

BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
Zacks Investment Research29 June 2023 Sentiment: POSITIVE

The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.

What type of business is BioSig Technologies?

BioSig Technologies, Inc., a medical technology company, focuses on deciphering the body's electrical signals starting with heart rhythms. It delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines. The company's product, the PURE EP Platform, provides real-time signal visualization allowing physicians to perform targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

What sector is BioSig Technologies in?

BioSig Technologies is in the Healthcare sector

What industry is BioSig Technologies in?

BioSig Technologies is in the Medical Devices industry

What country is BioSig Technologies from?

BioSig Technologies is headquartered in United States

When did BioSig Technologies go public?

BioSig Technologies initial public offering (IPO) was on 31 October 2014

What is BioSig Technologies website?

https://www.biosig.com

Is BioSig Technologies in the S&P 500?

No, BioSig Technologies is not included in the S&P 500 index

Is BioSig Technologies in the NASDAQ 100?

No, BioSig Technologies is not included in the NASDAQ 100 index

Is BioSig Technologies in the Dow Jones?

No, BioSig Technologies is not included in the Dow Jones index

When was BioSig Technologies the previous earnings report?

No data

When does BioSig Technologies earnings report?

The next expected earnings date for BioSig Technologies is 14 November 2024